誠如該第二份聯合公佈所載，百利保及富豪各自均需要更多時間備製將載於其各自通函 的相關資料，包括 (i) 債務聲明；(ii) 營運資金足夠聲明；及 (iii) 買賣交易之財務影響， 百利保及富豪各自已向聯交所申請豁免嚴格遵守上市規則第14.41(a) 條。 於二零二五年八月二十日，聯交所向百利保及富豪分別授出嚴格遵守上市規則第 14.41(a) 條之豁免（「該豁免」），條件為各自之通函將於二零二五年九月二日或之前寄 發。倘百利保及富豪的情況有變，聯交所可撤回或更改該豁免。 承董事會命 承董事會命 Paliburg Holdings Limited Regal Hotels International Holdings Limited 林秀芬 林秀芬 秘書 秘書 香港，二零二五年八月二十日 香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公佈之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不對因本聯合公佈全部或任何部份內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 (股份代號: 617) (股份代號: 78) 聯合公佈 豁免遵守 上市規則第 14.41 ( a )條 茲提述由 ...

誠如該聯合公佈所載，一份載有（其中包括）有關購股協議、買賣交易、購股協議項 下擬進行之交易之進一步詳情及根據上市規則項下須予披露之相關資料之通函，預 期將於刊發該聯合公佈後十五個營業日內（即二零二五年八月十九日或之前）寄發予 世紀城市股東。 由於世紀城市需要更多時間備製將載於通函的相關資料，包括 (i)未經審核備考財務 資料；(ii)債務聲明；(iii)營運資金足夠聲明；(iv)目標公司之財務資料；及(v)買賣 交易之財務影響，預期世紀城市之通函將於二零二五年九月二日或之前寄發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公佈之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本聯合公佈全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 （股份代號：355） （股份代號：617） （股份代號：78） 聯合公佈 延遲寄發通函 茲提述由Century City International Holdings Limited、Paliburg Holdings Limited及 Regal Hotels International Holdings Limite ...

Core Viewpoint - Sichuang Medical's involvement in financial fraud has led to criminal investigations, with the company cooperating with authorities during the ongoing inquiry [1][3][4]. Group 1: Investigation and Legal Actions - Sichuang Medical received a notice from Hangzhou Public Security Bureau regarding evidence collection for a fraud case related to securities issuance [1]. - The investigation focuses on past financial records and is linked to previous administrative penalties imposed by the Zhejiang Securities Regulatory Commission [3][4]. - The company was previously found to have inflated revenue and profits significantly, with a cumulative revenue inflation of 34.93 million yuan and profit inflation of 33.02 million yuan in 2019, representing 20.03% of total profit for that period [4][5]. Group 2: Financial Performance and Adjustments - In 2024, Sichuang Medical reported revenues of 690.77 million yuan, a decrease of 31.33% from the previous year, while the net loss was 501.51 million yuan, a reduction in losses by 42.64% compared to 2023 [9][10]. - The company has undergone significant restructuring, including the resignation of its former chairman and the sale of its subsidiary, which was the main platform for the fraudulent activities, for 300 million yuan [7][8]. - Following the divestment, the company aims to focus on the Internet of Things (IoT) business, shifting its growth strategy to "focus on IoT, reshape growth engines" [8]. Group 3: Regulatory Environment and Future Outlook - The recent increase in criminal accountability for financial fraud in the industry is highlighted by the Supreme Court and the China Securities Regulatory Commission's joint guidelines aimed at enhancing regulatory scrutiny and penalties for fraudulent activities [10]. - Sichuang Medical is actively engaging with investors regarding potential compensation plans and is committed to fulfilling its legal responsibilities [6].

Group 1 - The core point of the news is that Sichuang Medical (300078) has received a notice from the Hangzhou Public Security Bureau regarding an investigation into alleged fraudulent issuance of securities, and the company will cooperate with the investigation [1] - As of August 15, 2025, the investigation is still in the police investigation stage, and no clear conclusion has been reached [1] - The company has committed to timely information disclosure based on the progress of the case [1] Group 2 - Sichuang Medical's stock price has increased by 30.59% year-to-date, and the number of shareholders has grown by 51.39% compared to the end of 2024, reaching 73,800 [3] - Next week, 25 stocks will face a total unlock market value of 795.29 billion, with significant unlocks from companies like United Imaging Healthcare and GeKong Microelectronics [5][6] - Among the stocks facing unlock, some have seen institutional research, including New Coordinates and Leshan Electric Power, which recently reported on their technological advancements and operational updates [10]

Core Viewpoint - Sichuang Medical is under investigation by the Hangzhou Public Security Bureau for suspected fraudulent issuance of securities, marking the first time this issue has been publicly acknowledged since its listing in April 2010 [2][6]. Group 1: Investigation Details - On August 14, Sichuang Medical received a notice from the Hangzhou Public Security Bureau requesting evidence related to the investigation of the suspected fraudulent issuance of securities [6]. - The case is currently in the investigation stage, and no definitive conclusions have been reached yet [6]. Group 2: Financial Irregularities - The Administrative Penalty Decision issued by the Zhejiang Securities Regulatory Bureau on January 8, 2024, indicates that Sichuang Medical inflated its operating income by CNY 34.93 million and profits by CNY 33.02 million in 2019, and inflated operating income by CNY 60.96 million and profits by CNY 52.37 million in the first three quarters of 2020 [12]. - The company’s public offering documents contained significant false information, and its 2019 and 2020 annual reports included false records [12]. Group 3: Fundraising and Investment Issues - Sichuang Medical has faced continuous losses in recent years, with net profits of -CNY 8.78 billion in 2022, -CNY 8.74 billion in 2023, -CNY 5.02 billion in 2024, and -CNY 195.59 million in the first quarter of 2025 [19]. - The company has not fully invested the raised funds from its 2019 non-public stock issuance and 2021 convertible bond issuance into planned projects, with only CNY 30.54 million out of CNY 56.54 million planned for investment actually utilized [14][15]. - Specific projects, such as the Internet + AI medical innovation operation service project, have seen minimal investment compared to their planned amounts, with only CNY 0.23 million invested out of a planned CNY 3.33 billion [16][18]. Group 4: Recent Financial Performance - In 2024, Sichuang Medical reported operating revenue of CNY 690.77 million, a decrease of 31.33% compared to 2023, which had revenue of CNY 1.01 billion [20]. - The net profit attributable to shareholders was -CNY 501.51 million in 2024, showing an improvement of 42.64% from -CNY 874.35 million in 2023 [20].

Group 1 - The core issue involves a fraud investigation against the company by the Hangzhou Public Security Bureau regarding the alleged fraudulent issuance of securities [1] - The company has previously been under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, leading to administrative penalties [3] - The company was found to have fabricated significant false information in its public bond issuance documents, resulting in inflated revenue and profits for the years 2019 and 2020 [3][4] Group 2 - The company was penalized with a fine of 85.7 million yuan and its former chairman and general manager received individual fines and a 10-year market ban [5] - The company has faced significant revenue declines and continuous losses due to intense industry competition and business adjustments [5] - The company completed the divestiture of its 100% stake in its subsidiary, Medical Technology Co., Ltd., in August 2025 [5]

格隆汇8月13日丨富豪酒店(00078.HK)公布，公司将于2025年8月27日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...

香港，二零二五年八月十三日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示概不對因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致之 任何損失承擔任何責任。 於本公佈刊發日期，董事會包括下列成員： (股份代號：78) 董事會會議日期 Regal Hotels International Holdings Limited（「本公司」）之董事會（「董事會」）宣佈本公 司將於二零二五年八月二十七日（星期三）舉行董事會會議，藉以批准發佈本集團（包 括本公司及其附屬公司）截至二零二五年六月三十日止六個月之中期業績及其他相關事 宜。 承董事會命 Regal Hotels International Holdings Limited 林秀芬 秘書 羅旭瑞先生 （主席兼行政總裁） 羅寶文女士 （副主席兼董事總經理） 梁蘇寶先生 羅俊圖先生 獨立非執行董事： 吳季楷先生 簡麗娟女士 温子偉先生 羅文鈺教授 執行董事： 非執行董事： 蔡志明博士，GBS，JP （副主席） 楊碧瑤女士，JP 伍頴梅女士，JP 黃之強先生 ...

Core Viewpoint - The long-term service contract between Beijing University Pharmaceutical's wholly-owned subsidiary and Peking University International Hospital will terminate in May 2025, leading to significant operational challenges for the company [1][3]. Group 1: Business Impact - The termination of the contract is expected to result in a revenue decrease of approximately 600 million yuan (29.13% of the latest audited revenue) and a net profit decrease of about 40 million yuan (28.99% of the latest audited net profit) starting from June 2025 [3]. - From 2026 onwards, the company may face a revenue reduction of around 1.027 billion yuan (49.85% of the latest audited revenue) and a net profit decrease of approximately 68.69 million yuan (49.78% of the latest audited net profit) [3][5]. Group 2: Strategic Adjustments - The company is exploring new directions for the transformation of its subsidiary to mitigate the impact of the contract termination, although the success of this transformation remains uncertain [5]. - A strategic adjustment of the production and manufacturing system is proposed to enhance operational efficiency and core competitiveness, focusing on establishing a manufacturing subsidiary [6]. Group 3: Corporate Identity Changes - The company is initiating a name change process to gradually achieve a "de-Peking University" status, following changes in its actual controlling shareholder [7]. - The company primarily engages in the research, production, and sales of chemical drug formulations, pharmaceutical distribution, and medical services [7]. Group 4: Market Position - As of August 11, the company's stock price was 6.93 yuan per share, with a total market capitalization of 4.1 billion yuan [8].

Core Viewpoint - Beijing Medical Pharmaceutical Company (北大医药) is facing significant challenges as its wholly-owned subsidiary, Beijing Beiyi Medical Co., Ltd. (北医医药), will terminate its long-term service contract with Peking University International Hospital (国际医院) in May 2025, leading to substantial revenue and profit declines [1][5][6] Group 1: Contract Termination and Financial Impact - The long-term service contract between 北医医药 and 国际医院, which has been in place for three years, is set to end in May 2025, resulting in a projected revenue decrease of approximately 600 million yuan (about 6 billion) and a net profit reduction of around 40 million yuan (about 4000) [1][4] - The termination of the contract is expected to cause a significant operational strain on the company, with potential layoffs and a shift in business focus [5][6] Group 2: Future Business Direction and Risks - Following the termination, 北医医药 has not identified alternative business opportunities, which raises concerns about a complete halt in its main operations and the risk of company closure or transformation [5][6] - The company anticipates a further revenue decline of approximately 1.027 billion yuan (about 10.27 billion) and a net profit decrease of around 68.69 million yuan (about 6869) starting in 2026, which could represent nearly 50% of its most recent audited revenue and profit figures [6]